Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer
- 31 December 1991
- journal article
- Published by Elsevier BV in European Journal of Cancer and Clinical Oncology
- Vol. 27 (12), 1617-1620
- https://doi.org/10.1016/0277-5379(91)90427-f
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Comparison of the cytotoxicity of amsacrine and its analogue CI-921 against cultured human and mouse bone marrow tumour cellsEuropean Journal of Cancer and Clinical Oncology, 1990
- Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase IIEuropean Journal of Cancer and Clinical Oncology, 1988
- Effects of CI-921, an analogue of amsacrine, on advanced Lewis lung tumours in mice: Relevance to clinical trialsEuropean Journal of Cancer and Clinical Oncology, 1988
- Comparison of in Vitro activity of cytotoxic drugs towards human carcinoma and leukaemia cell linesEuropean Journal of Cancer and Clinical Oncology, 1986
- Etoposide (VP-16) in the treatment of lung cancerCancer Treatment Reviews, 1983
- Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the futureCancer Treatment Reviews, 1983
- Reporting results of cancer treatmentCancer, 1981